{"disease":{"id":"leukemia-juvenile-myelomonocytic","name":"leukemia juvenile myelomonocytic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00898079","title":"Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2545,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04726241","title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"PedAL BCU, LLC","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT02790515","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00566696","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT05735717","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT01445080","title":"Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03849651","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05515029","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT04024761","title":"A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT01384513","title":"A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT06247787","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00852709","title":"Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT00450450","title":"Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT02458235","title":"Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT03843528","title":"Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Johns Hopkins All Children's Hospital","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}